Antibiotic treatment of clostridial colitis

Česká verzia

Authors: J. Beneš; S. Polívková
Authors place of work: Klinika infekčních nemocí 3. LF UK, Nemocnice Na Bulovce, Praha
Published in the journal: Epidemiol. Mikrobiol. Imunol. 65, 2016, č. 1, s. 15-24
Category: Review Article

Summary

The advantages and disadvantages of various antibiotics used in the treatment of Clostridium difficile infection (CDI) are compared with respect to their pharmacokinetic and pharmacodynamic properties. Recommendations are made for their optimal use in clinical practice. Metronidazole is suitable for the treatment of mild forms of CDI which are essentially self-limiting. Vancomycin kills clostridia reliably but the treatment is encumbered with considerable risk of recurrence. This can be decreased by shortening the treatment to seven days and then switching to a (pulse, taper, chaser) regimen to prevent recurrence or by active restoration of the intestinal ecosystem (fecal transplant). Fidaxomicin works faster than vancomycin and is associated with a lower risk of recurrence. Thus, it can be profitably used in patients with impending ileus and also in those whose medical condition does not allow prolonged treatment. The duration of fidaxomicin treatment could be reduced to as few as five days. Rifaximin does not have a clear place in the treatment of CDI because no compelling data are available on its efficacy in this disease. The risk of resistance is also important. Tigecycline is a promising antibiotic for parenteral use. According to the available data, it should be more effective than intravenous metronidazole which has been considered the drug of choice.

Clostridial colitis is associated with intestinal dysmicrobia which is the major cause of recurrence. Severe dysmicrobia cannot be treated by antibiotics but only by gut flora restoration; stool transplant from a healthy donor is the only proven therapy for this condition.

Keywords:
Clostridium difficile – clostridial colitis– metronidazole – vancomycin – fidaxomicin – rifaximin – tigecycline

Zdroje

1. Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet, 2011;377(9759):63–73.

2. Beneš J, Husa P, Nyč O, Polívková S. Doporučený postup diagnostiky a léčby kolitidy vyvolané Clostridium difficile. Klin. Mikrobiol. Inf. Lék., 2014;20(2):56–66.

3. Debast SB, Bauer MP, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): update of the treatment guidance document for Clostridium difficile infection (CDI). Dostupné z: http://onlinelibrary.wiley.com/doi/10.1111/1469-0691.12418/pdf.

4. Havlík J, a kol. Infektologie. Učebnice pro lékařské fakulty. Praha: Avicenum, 1990, p. 151.

5. Gerber M, Walch C, Löffler B, et al. Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile. J Med Microbiol, 2008;57(6):776–783.

6. Grayson ML, et al. (eds): Kucers‘ The Use of Antibiotics, 6th ed. London: Hodder Arnold, 2010.

7. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut, 1986;27(10):1169–1172.

8. Soriano MM, Johnson S. Treatment of Clostridium difficile infections. Infect Dis Clin North Am, 2015;29(1):93–108.

9. Aradhyula S, Manian FA, Hafidh SA, Bhutto SS, Alpert MA. Significant absorption of oral vancomycin in a patient with Clostridium difficile colitis and normal renal function. South Med J, 2006;99(5):518–520.

10. Chihara S, Shimizu R, Furukata S, Hoshino K. Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis. Scand J Infect Dis, 2011; 43(2):149–150.

11. Keighley MR, Burdon DW, Arabi Y, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J, 1978;2(6153):1667–1669.

12. Fekety R, Silva J, Kauffman C, Buggy B, Deery HG. Treatment of antibiotic-associated Clostridium difﬁcile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med, 1989;86:15–19.

13. Garey KW, Ghantoji SS, Shah DN, et al. A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection. J Antimicrob Chemother, 2011;66(12):2850–2855.

14. Ritter AS, Petri WA Jr. New developments in chemotherapeutic options for Clostridium difficile colitis. Curr Opin Infect Dis, 2013;26(5):461–470.

15. Johnson S, Schriever C, Patel U, et al. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe, 2009;15(6):290–291.

16. Soriano MM, Danziger LH, Gerding DN, Johnson S. Novel fidaxomicin treatment Regimens for patients with multiple Clostridium difficile infection recurrences that are refractory to standard therapies. Open Forum Infect Dis, 2014;1(2): ofu069.

17. Mullane K. Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. Ther Adv Chronic Dis, 2014;5(2):69–84.

18. Shue YK, Sears PS, Shangle S, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother, 2008;52(4):1391–1395.

19. Babakhani F, Bouillaut L, Sears P, et al. Fidaxomicin inhibits toxin production in Clostridium difficile. J Antimicrob Chemother, 2013;68(3):515–522.

20. Babakhani F, Gomez A, Robert N, Sears P. Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents Chemother, 2011;55(9):4427–4429.

21. Babakhani F, Bouillaut L, Gomez A, et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis, 2012;55(Suppl 2):S162–169.

22. Mullane KM, Miller MA, Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis, 2011;53(5):440-447.

23. Chaparro-Rojas F, Mullane KM. Emerging therapies for Clostridium difficile infection – focus on fidaxomicin. Infect Drug Resist, 2013;6:41–53.

24. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother, 1995;36(4):673–679.

25. Al-Nassir WN, Sethi AK, Nerandzic MM, et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis, 2008;47(1):56–62.

26. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med, 2011;364(5):422–431.

27. Orenstein R. Fidaxomicin failures in recurrent Clostridium difficile infection: a problem of timing. Clin Infect Dis, 2012;55(4):613–614.

28. Soriano MM, Danziger LH, Gerding DN, Johnson S. Novel fidaxomicin treatment regimens for patients with multiple Clostridium difficile infection recurrences that are refractory to standard therapies. Open Forum Infect Dis, 2014;1(2):ofu069.

29. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy, 2005;51(Suppl 1):36–66.

30. Nelson RL, Kelsey P, Leeman H, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev, 2011; CD004610.

31. Basu P, Dinani A, Rayapudi K, et al. Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. Therap Adv Gastroenterol, 2010; 3: 221–225.

32. Mattila E, Arkkila P, Mattila PS, et al. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther, 2012;37:122–128.

33. Carman RJ, Boone JH, Grover H, et al. In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy. Antimicrob Agents Chemother, 2012;56:6019–6020.

34. Hoffmann M, DeMaio W, Jordan RA, et al. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos, 2007;35(9):1543–1553.

35. Aldape MJ, Heeney DD, Bryant AE, Stevens DL. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile. J Antimicrob Chemother, 2015;70(1): 153–159.

36. Theriot CM, Schumacher CA, Bassis CM, et al. Effects of tigecycline and vancomycin administration on established Clostridium difficile infection. Antimicrob Agents Chemother, 2015;59(3):1596–1604.

37. Britt NS, Steed ME, Potter EM, Clough LA. Tigecycline for the Treatment of Severe and Severe Complicated Clostridium difficile Infection. Infect Dis Ther, 2014. [Epub ahead of print].

38. Larson KC, Belliveau PP, Spooner LM. Tigecycline for the treatment of severe Clostridium difficile infection. Ann Pharmacother, 2011;45(7-8):1005–1010.

39. de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother, 1992;36(10):2192–2196.

40. Wenisch C, Parschalk B, Hasenhündl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis, 1996;22(5):813–818.

41. Mascio CT, Chesnel L, Thorne G, Silverman JA. Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother, 2014;58(7):3976–3982.

42. Alam MZ, Wu X, Mascio C, et al. Mode of action and bactericidal properties of surotomycin against growing and non-growing Clostridium difficile. Antimicrob Agents Chemother, 2015. [Epub ahead of print]

43. Chilton CH, Crowther GS, Todhunter SL, et al. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. J Antimicrob Chemother, 2014;69(9):2426–2433.

44. Locher HH, Seiler P, Chen X, et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections. Antimicrob Agents Chemother, 2014;58(2):892–900.

45. Baldoni D, Gutierrez M, Timmer W, Dingemanse J. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother, 2014;69(3):706–714.

46. Beneš J, Husa P, Nyč O. Doporučený postup diagnostiky a léčby kolitidy vyvolané Clostridium difficile. Klin mikrobiol inf lék, 2012;18(5):160–167.

47. Friedenberg F, Fernandez A, Kaul V, et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum, 2001;44:1176–1180.

48. Longin P, Valeckova M, Bilek A, et al. Local application of fidaxomicin in a patient with subtotal colectomy following recurring Clostridium difficile infection. JMM Case Reports, 2014;1. Published online 2014.

49. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol, 2010;31(5):431–455.

50. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother, 1995;36(4):673–679.

51. Al-Nassir WN, Sethi AK, Nerandzic MM, et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis, 2008;47(1):56–62.

52. Thielman NM, Wilson KH. Antibiotic-associated colitis. In: Manell GL, Bennett JE, Dolin R (eds.): Mandell, Douuglas, and Bennett´s Principles and Practice of Infectious Diseases, 7th ed. Churchill Livingstone Elsevier 2010, pp 1375–1388.

53. Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis, 2014;59(3):345–354.

54. O'Horo JC, Jindai K, Kunzer B, Safdar N. Treatment of recurrent Clostridium difficile infection: a systematic review. Infection, 2014;42(1):43–59.

55. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med, 2010;362(3):197–205.

56. Mattila E, Anttila VJ, Broas M, et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis, 2008;40(9):702–708.

57. Fitzpatrick LR. Probiotics for the treatment of Clostridium difficile associated disease. World J Gastrointest Pathophysiol, 2013;4(3):47–52.

58. Thygesen JB, Glerup H, Tarp B. Saccharomyces boulardii fungemia caused by treatment with a probioticum. BMJ Case Reports, 2012;10.1136/bcr.06.2011.4412.

59. Yakob L, Riley TV, Paterson DL, Clements AC. Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. BMC Infect Dis, 2013;13:376.

60. Borgia G, Maraolo AE, Foggia M, et al. Fecal microbiota transplantation for Clostridium difficile infection: back to the future. Expert Opin Biol Ther, 2015;15(7):1001–1014.

61. http://www.rebiotix.com/index.php/rebiotix-clinical-program/punch-cd-2-clinical-trial

62. Pattani R, Palda VA, Hwang SW, Shah PS. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis. Open Med, 2013;7(2):e56–67.

63. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA, 2012;307(18): 1959–1969.

64. Hickson M. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol, 2011;4(3):185–197.

65. Hempel S, Newberry S, Ruelaz A, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess, 2011;(200):1–645.

66. Issa I, Moucari R. Probiotics for antibiotic-associated diarrhea: Do we have a verdict? World J Gastroenterol, 2014;20(47):17788–1795.

67. Beniwal RS, Arena VC, Thomas L, et al. A randomized trial of yogurt for prevention of antibiotic-associated diarrhea. Dig Dis Sci, 2003;48(10):2077–2082.

68. Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, 2013; 382(9900):1249–1257.

69. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature, 2011;473(7346):174–180.

70. Davenport ER, Mizrahi-Man O, Michelini K, et al. Seasonal variation in human gut microbiome composition. PLoS One, 2014;9(3): e90731.

71. Freeman J, Vernon J, Morris K, et al. Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes. Clin Microbiol Infect, 2015;21(3): 248.e9–248.e16.

72. Cornely OA, Nathwani D, Ivanescu C, et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother, 2014;69(11):2892–2900.

73. Crook DW, Walker AS, Kean Y, et al. Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials. Clin Infect Dis, 2012;55(Suppl 2):S93–103.

74. Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA, 2015;313(4):398–408.

75. Di X, Bai N, Zhang X, et al. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Braz J Infect Dis, 2015 [Epub ahead of print].

Štítky

Hygiene and epidemiology Medical virology Clinical microbiology

Článek The prevalence of Candida pelliculosa, Candida utilis, and Candida fabianii in the Olomouc University Hospital: epidemiological study

Článek The benefit from mumps virus IgG antibody avidity testing in the population with high vaccine coverage in the context of other serological methods for laboratory diagnosis of mumps and the current epidemiological

Článek Assessment of invalidity as a result of infectious diseases

Článek Infectious and other somatic comorbidity in problem drug users – results of a cross-sectional study with medical examination

Článek Hepatitidis E virus

Článek Prevalence of infectious complications in burn patients requiring intensive care: data from a pan-European study

Článek Influenza in the pediatric population in Istanbul: a one center experience 2009–2014

Článok vyšiel v časopise

Epidemiology, Microbiology, Immunology

2016 Číslo 1

Najčítanejšie v tomto čísle